Form 4: C4 Therapeutics CFO Reports Stock Transaction
Insider Transaction (Form 4)
Kendra Adams, Chief Financial Officer of C4 Therapeutics, Inc., reported multiple transactions in common stock on September 18, 2026.
Summary
- Option exercise/conversion: acquired 6,250 Common Stock on September 18, 2026; holds 385,098 after (Direct).
- Tax/exercise-price withholding: disposed of 2,775 Common Stock at $3.39 ($9,407) on September 18, 2026; holds 382,323 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Kendra Adams — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-18 | Option exercise/conversion | Common Stock | 6,250 | — | — | 385,098 |
| 2026-09-18 | Tax/exercise-price withholding | Common Stock | 2,775 | $3 | $9.4K | 382,323 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-18 | Option exercise/conversion (6,250 shares) |
| 2026-09-18 | Tax/exercise-price withholding (2,775 shares) |
Keywords
insider transaction, Form 4, CCCC, C4 Therapeutics, Inc., neutral, Kendra Adams
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.